CVS Caremark (CVS) said Tuesday it has reached a global settlement with the Federal Trade Commission, which further advances the company's ability to deliver affordable prescription drugs.
The settlement resolves all outstanding FTC litigation and investigations related to CVS Health, involving rebate, pharmacy network contracting, and vertical integration issues, the company said.
Many of the measures in the agreement align with CVS Caremark's current affordability and transparency efforts, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model, each meant to reduce patient costs and offer greater clarity about drugs, the company added.
Price: $105.94, Change: $+0.04, Percent Change: +0.04%